Managing Editor
@ShahidNShah
@ShahidNShah
The PROphet report shows a prediction of the patient’s clinical benefit (progression-free survival 12 months) from PD-1PD-L1 inhibitor immunotherapy-based treatment plans.Combining these findings with a patient’s PD-L1 level allows for a clear distinction between those who will benefit from immunotherapy alone versus immunotherapy combined with chemotherapy. This may improve the patient’s overall response rate.PROphet thereby addresses one of the most common daily dilemmas of the oncologist with an accuracy and level of resolution that simply does not exist today.
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2025 Netspective Foundation, Inc. All Rights Reserved.
Built on Jul 1, 2025 at 1:20pm
